Overview

Assess the Effect of Zolpidem, Silenor & Placebo on Arousability, Ataxia/Balance & Cognition in Healthy Volunteers

Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase IV, randomized, double-blind, placebo-controlled, four-arm crossover study. The study will assess the effects of a single dose of Silenor 6 mg compared with matching placebo and a single dose of zolpidem 10 mg compared to its matching placebo at the respective T-max in normal healthy adult male volunteers. The study will be conducted in approximately 52 male subjects
Phase:
Phase 4
Details
Lead Sponsor:
Currax Pharmaceuticals
Pernix Theraputics LLC
Collaborator:
Henry Ford Hospital
Treatments:
Doxepin
Zolpidem